Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fentanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentanyl SCHEMBL8804 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4326756 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL28383546 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4353786 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4321837 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4324385 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4971300 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL18249370 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL22637301 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL242876 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054028-B9 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD (IE) | 2012-09-26 | — | — | EP | claimed |
| EP-2054028-B1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD (IE) | 2012-06-27 | — | — | EP | claimed |
| US-20090246245-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LIMITED (IE) | 2009-10-01 | — | — | US | claimed |
| EP-2054028-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | Mediolanum Pharmaceuticals Limited (IE) | 2009-05-06 | — | — | EP | claimed |
| WO-2008015232-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD. (IE) | 2008-02-07 | — | — | WO | claimed |
| CN-1236758-C | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2006-01-18 | — | — | CN | claimed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | claimed |
| CN-118043049-A | Sotosib and EGFR antibodies for the treatment of cancers comprising KRAS G12C mutations | 安进公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240066024-A1 | TRANSMUCOSAL DELIVERY DEVICE WITH ENHANCED UPTAKE | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4121746-A1 | IN-FIELD COLOUR TEST FOR SCREENING FENTANYL AND ANALOGUES THEREOF | University Of Technology Sydney (AU) | 2023-01-25 | — | — | EP | disclosed |
| EP-4117661-A1 | FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING | Regents of the University of Minnesota (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021184082-A1 | IN-FIELD COLOUR TEST FOR SCREENING FENTANYL AND ANALOGUES THEREOF | UNIVERSITY OF TECHNOLOGY SYDNEY (AU) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021183913-A1 | FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20040013716-A1 | Transdermal analgesic systems with reduced abuse potential | DURECT CORPORATION | 2004-01-22 | — | — | US | disclosed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | disclosed |
| WO-2003090729-A1 | TRANSDERMAL ANALGESIC SYSTEMS WITH REDUCED ABUSE POTENTIAL | ALZA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| CN-1428607-A | Method for detection or quantitative determination of metabolite of fentanyl or metabolite of fentanyl analogues and kit | LANDAUKES LAB CO LTD (GB) | 2003-07-09 | — | — | CN | disclosed |
| US-20030099687-A1 | Combination for the treatment of endothelial damage | LICENTIA LTD. (FI) | 2003-05-29 | — | — | US | disclosed |
| US-5006342-A | Resilient transdermal drug delivery device | CYGNUS CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| US-4906463-A | Transdermal drug-delivery composition | CYGNUS RESEARCH CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066024-A1 | TRANSMUCOSAL DELIVERY DEVICE WITH ENHANCED UPTAKE | ABCB11, SLC35A1, OPRM1 | OPRM1 3/4885OPRD1 21/4885OPRK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.